Aclaris Therapeutics (ACRS) Non-Current Deffered Revenue (2014 - 2026)

Aclaris Therapeutics' Non-Current Deffered Revenue history runs 5 years deep, the most recent figure standing at $15.3 million for Q1 2026.

• On a quarterly basis, Non-Current Deffered Revenue fell 20.42% year-over-year to $15.3 million in Q1 2026; TTM through Mar 2026 was $15.3 million, a 20.42% decrease from a year earlier, with the FY2025 full-year figure at $16.2 million, down 19.31% from the prior year.
• Non-Current Deffered Revenue fell to $15.3 million in Q1 2026 per ACRS's latest filing, from $16.2 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $21.2 million in Q3 2024 and bottomed at $15.3 million in Q1 2026.
• The 3-year median for Non-Current Deffered Revenue is $18.2 million (2025), against an average of $18.2 million.
• Across the five-year window, Non-Current Deffered Revenue fell 17.42% in 2025 and declined 20.42% in 2026, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $20.0 million in 2024, then fell by 19.31% to $16.2 million in 2025, then slipped by 5.46% to $15.3 million in 2026.
• Per Business Quant, the three latest ACRS Non-Current Deffered Revenue figures stand at $15.3 million (Q1 2026), $16.2 million (Q4 2025), and $17.5 million (Q3 2025).